H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $3.50 from $7 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect the Q2 report and private placement expected to close on August 13. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals trading halted, news pending
- X4 Pharmaceuticals Announces $60M Equity Financing
- X4 Pharmaceuticals announces $60M financing, management changes
- X4 Pharmaceuticals Advances Phase 3 Study for WHIM Syndrome Treatment
- X4 Pharmaceuticals Advances Phase 3 Study of Mavorixafor for WHIM Syndrome